PliaFX Flo Subtalar Fusion Study
A Prospective Pilot Comparative Study to Evaluate the Efficacy of PliaFX® Flo Allograft in Subtalar Arthrodesis at St. Paul's Hospital in Vancouver, Canada
During a subtalar fusion, the bones making up the subtalar joint (talus and calcaneus) are permanently fused together. In the procedure, any damaged cartilage and bone at the subtalar joint is removed, then screws are inserted into the joint to fuse the bones together. Depending on the surgeon, a bone graft is sometimes applied between the bones prior to screw insertion to aid in bone bridging (growth of bone into the fusion site). Participants who consent to this study and are assigned to the PliaFX® Flo Allograft group, will receive PliaFX® Flo Allograft (human tissue donated from a donor) at the fusion site. The PliaFX® Flo system is demineralized bone fibers (hard minerals removed from bone using acid) in a sterile syringe that allows for delivery into small areas where bone graft is needed to assist bone fusion. The allograft bone fibers are produced from donated human cadaver (deceased human) bone.
This study aims to determine whether the use of PliaFX® Flo Allograft in subtalar fusions will improve functioning and healing of the bone and cartilage for patients like you. Participants who are interested will discuss with their surgeon and be randomly assigned to one of the two study procedures below. The patient will not know what group they are in until after all data has been collected and all study visits are complete.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Biraj Bora
- Phone Number: 604-813-0889
- Email: biraj.bora@phc.ca
Study Locations
-
-
British Colombia
-
Vancouver, British Colombia, Canada, V6Z 1Y6
- St. Paul's Hospital
-
Contact:
- Biraj Bora
- Phone Number: 604-813-0889
- Email: biraj.bora@phc.ca
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject is at least 19 years of age.
- The subject is considered to be skeletally mature.
- The subject qualifies for subtalar fusion based on physical examination and/ or past medical history including isolated osteoarthritis, post-traumatic, degenerative, or rheumatoid arthritis of the ankle.
- The subject experiences severe pain in the subtalar joint that could not be cured with non-operative treatment options.
- The patient may undergo a subtalar fusion as part of a triple arthrodesis.
- The patient may have forefoot pathology addressed by either prior or concurrent surgery (osteotomies or fusions).
- The patient consented for either an arthroscopic or open procedure.
- The subject is able to comply with all post-operative evaluations and visits.
- The subject consents to and will receive either no graft or PliaFX® Flo allograft during their surgery
Exclusion Criteria:
-
The subject has:
- Severe osteoporosis
- Neuromuscular impairment
- Prior infection in the affected joint
-
The subject currently has acute infections that, in the opinion of the Investigator, may complicate healing.
-
The subject has a known or suspected allergy to any of the processing reagents listed in the packet insert (alcohol, glycinate buffer, and glycerol).
-
The subject is renal compromised.
-
The subject has a major risk factor for non-union (ex. poorly controlled diabetes or current smoker).
-
The subject is undergoing a revision of a prior subtalar fusion.
-
The subject has had a prior ankle joint fusion.
-
An ankle joint replacement or ankle joint fusion may be performed during the same sitting.
-
The subject has a BMI of > 50 kg/m2.
-
The subject is known to be pregnant, or plans to become pregnant during the study period
-
The investigator judges the subject to be unable or unlikely to remain compliant to follow-up due to a physical or mental condition (ex. currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.).
-
The subject is unable to provide informed consent.
-
The subject is unable to communicate with the research team.
-
The subject is unable to comply with follow-up.
-
The subject has a history of substance addiction (e.g. recreational drugs, narcotics, or alcohol) within 12 months prior to screening for study entry
-
The subject will be receiving a structural autograft or allograft (such as a femoral head graft or tri cortical iliac crest graft) to fill a defect greater than 1cm3
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PliaFX Flo Allograft
Participant will receive PliaFX Flo during their Subtalar Arthrodesis procedure. |
Participant will receive the PliaFX Flo Allograft during their Subtalar Arthrodesis procedure. |
|
No Intervention: No Graft
Participant will receive no graft during their Subtalar Arthrodesis procedure. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bone Bridging Percentage
Time Frame: Enrollment to last Follow-up visit (52 weeks)
|
Bone bridging percentage measured by CT scans at 12, 24, and 52 weeks post-operatively. |
Enrollment to last Follow-up visit (52 weeks)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Foot and Ankle Measure (FAAM) Questionnaire
Time Frame: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 0, maximum value of 100, and lower scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
Current Health Assessment Questionnaire
Time Frame: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 0, maximum value of 100, and higher scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
American Academy of Orthopaedic Surgeons (AAOS) Foot and Ankle Questionnaire
Time Frame: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 0, maximum value of 100, and lower scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
Demographics Questionnaire
Time Frame: Enrollment to last follow up visit (52 weeks)
|
Enrollment to last follow up visit (52 weeks)
|
|
|
Ankle Osteoarthritis Scale
Time Frame: Enrollment to last follow up visit (52 weeks)
|
Minimum value of 1, maximum value of 100, and higher scores are worse. |
Enrollment to last follow up visit (52 weeks)
|
|
SF-36 Health Survey
Time Frame: Enrollment to last follow up visit (52 weeks)
|
Enrollment to last follow up visit (52 weeks)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- H26-01617
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.